Warning: session_start(): open(/opt/alt/php74/var/lib/php/session/sess_fda83d27682868c5724600afb953fe53, O_RDWR) failed: Disk quota exceeded (122) in /home/useaicwl/public_html/wp-content/themes/mushroomstocks/functions.php on line 278

Warning: session_start(): Failed to read session data: files (path: /opt/alt/php74/var/lib/php/session) in /home/useaicwl/public_html/wp-content/themes/mushroomstocks/functions.php on line 278
GW Pharmaceuticals (GWPH) Reports Poor Stage 3 Clinical Data. - Mushroomstocks | Mushroomstocks
Albert Labs announces Strategic Investment from Cantheon Capital LLC for First In-Human TrialsMindMed Reports Full Year 2022 Financial Results and Business HighlightsCybin to Participate in the Oppenheimer 33rd Annual Healthcare ConferenceNuminus to Participate in the Sequire Cannabis & Psychedelics Conference on Wednesday, April 5, 2023Braxia Scientific Provides Update on Proposed Irwin Transaction; Company Retains Strategic Clinical Assets and Ketamine Numinus Announces Four Peer-Reviewed Publications from its Chief Clinical Officer in 2023Irwin Naturals Signs Letter of Intent to Acquire Braxia ScientificNuminus Wellness Inc. Reports Q1 2023 ResultsIrwin Naturals and Braxia Scientific Announce Partnership for In-Human Clinical Studies Supporting Pharmaceutical CompanNuminus Develops Mushroom Tea for Use in Psychedelic ResearchIs the Psychedelic Sector Poised for a Comeback?!?PSYC + Nucleus Form New Partnership to Develop and Launch Psychedelic FinderWhat You Need to Know About Numinus Wellness…Numinus provides update on acquisition integration and announces new client financing optionsPSYC Corp’s Psychedelic Spotlight Surpasses One Million Page Views for Fourth Consecutive MonthNuminus to Participate in the H.C. Wainwright 24th Annual Global Investment Conference on September 12-14, 2022The Psychedelic Sector is Quietly Outperforming the S&P 500PSYC Completes and Publishes 2021 Audited Financials; Will Begin Audit of Q1 & Q2 2022Numinus to Participate in the H.C. Wainwright 24th Annual Global Investment Conference on September 12-14, 2022PSYC’s Bonfire Platform Development Progresses; Will Host Free Virtual Community Event on August 29th

GW Pharmaceuticals (GWPH) Reports Poor Stage 3 Clinical Data.

Oct 27, 2015 • 12:49 PM EDT
2 MIN READ  •  By Michael Berger
Share Share - Facebook Share - Twitter

Although it looks like shares of GW Pharmaceuticals plc (GWPH) recently found a bottom in the high $70s, we expect to see further weakness after the company reported poor top-line results from its Phase 3 trials for its Sativex product.

Today, GWPH and Otsuka Pharmaceutical Development & Commercialization, Inc. reported top-line results from the remaining two Phase 3 trials for Sativex in the treatment of pain in patients with advanced cancer. Consistent with the previously announced results from the initial Phase 3 trial, remaining trials failed to show superiority over placebo.

A pre-specified pooled analysis of patients across the two Phase 3 trials did show a statistically significant improvement for Sativex compared with placebo. GWPH and Otsuka have submitted a request to meet with the FDA to discuss the clinical relevance of this data and to determine potential paths forward.

CEO Justin Gover said the results were not a surprise and the company is encouraged by data across the trials which consistently show positive outcomes for United States patients when analyzed as a separate group of subjects. Gover thinks that this finding may provide important guidance in determining the optimal target patient population for Sativex.

Signs agreement with Government of New South Wales in Australia

Concurrent with this announcement, GWPH announced that they signed a Memorandum of Understanding (MOU) with the Government of New South Wales in Australia to progress a research program for Epidiolex and CBDV in children with severe, drug resistant childhood epilepsy. The MOU will facilitate:

-A Phase 2 clinical trial for GW’s cannabidivarin (CBDV) product

-A compassionate access program for Epidiolex which is in Phase 3 clinical trials with the FDA for Dravet syndrome and Lennox-Gastaut syndrome

-Provision for New South Wales to host additional Phase 3 clinical trials of Epidiolex

-A Phase 4 clinical trial of Epidiolex based on Phase 3 studies

As part of the agreement, New South Wales Government is providing $3.5 million to the Sydney Children’s Hospitals Network to lead the Phase 2 clinical trial of CBDV which is expected to commence in 2016.

Selloff creates opportunity

While this development is disappointing, we expect to see the market over react to this news. We view this weakness as a buying opportunity because most of GWPH’s upside is related to its Epidiolex product.

Bank of America (BAC) recently raised their price target on GWPH from $115 to $155. BAC raised its price target because of the positive response patients had from the company’s Epidiolex product. The $155 price target includes: $133 for Epidiolex, $7 for CBDV, $4 for Sativex royalties and $12 for cash.

Share Share - Facebook Share - Twitter


Authored By

Michael Berger

Michael Berger is Managing Partner of StoneBridge Partners, LLC and Founder of Mushroomstocks.com. Prior to entering the cannabis industry, Michael was an Equity Research Analyst at Raymond James Financial covering the Energy Sector. Michael has been featured in publications such as The Street, Bloomberg, US Money News, and hosts various cannabis events across North America.


Top Stories

Get the Latest Cannabis News & Stock Picks.

Enter your email below to join the official Mushroomstocks newsletter.

 All good -- no spamming here.

The psychedelics sector is starting to take off as smart money begins to position itself across the industry.

Stay updated with all latest updates,upcoming events & much more.

Fatal error: Uncaught ErrorException: md5_file(/home/useaicwl/public_html/wp-content/litespeed/css/9e01ea048126819ef0a230de44c5e303.css.tmp): failed to open stream: No such file or directory in /home/useaicwl/public_html/wp-content/plugins/litespeed-cache/src/optimizer.cls.php:126 Stack trace: #0 [internal function]: litespeed_exception_handler(2, 'md5_file(/home/...', '/home/useaicwl/...', 126, Array) #1 /home/useaicwl/public_html/wp-content/plugins/litespeed-cache/src/optimizer.cls.php(126): md5_file('/home/useaicwl/...') #2 /home/useaicwl/public_html/wp-content/plugins/litespeed-cache/src/optimize.cls.php(797): LiteSpeed\Optimizer->serve('https://mushroo...', 'css', true, Array) #3 /home/useaicwl/public_html/wp-content/plugins/litespeed-cache/src/optimize.cls.php(319): LiteSpeed\Optimize->_build_hash_url(Array) #4 /home/useaicwl/public_html/wp-content/plugins/litespeed-cache/src/optimize.cls.php(252): LiteSpeed\Optimize->_optimize() #5 /home/useaicwl/public_html/wp-includes/class-wp-hook.php(310): LiteSpeed\Optimize->f in /home/useaicwl/public_html/wp-content/plugins/litespeed-cache/src/optimizer.cls.php on line 126